Oxford Biomedica - A leading, fully integrated, cell and gene therapy group focused on developing life-changing treatments for serious diseases, Oxford Biomedica is your partner of choice for viral vector development scale-up, analytics and GMP processing.
Leverage our expertise and state-of-the-art bioprocessing facilities and purpose built laboratories to help to achieve commercialisation of your viral vector-based products.
Using LentiVector®, our sector leading lentiviral vector platform, Oxford Biomedica develops in vivo and ex vivo products both in-house and with partners, including with Novartis, Bristol Myers Squibb, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, Cabaletta Bio, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations. Additionally, Oxford Biomedica has a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222.
Oxford Biomedia Solutions, a US-based subsidiary, offers a plug and play platform that is capable of achieving both high titer and high product quality vector for partners. The platform has already been proven with six separate new product INDs and CTAs. High titer, high product quality, proven expertise, and speed are the foundation of the platform. This unique platform and fully integrated end-to-end capabilities, from vector design and process development through to clinical trials. For more information, contact us at firstname.lastname@example.org.
Discover how we drive credible science to help you realise incredible results - visit www.oxb.com or email email@example.com